Latest News

The ITN's START research trial for new-onset type 1 diabetes has received the approval of its Data Safety and Monitoring Board to accept patients aged 12-18 years into the study. The decision was made after a review of safety data from the initial group of 10 adult subjects enrolled into the study. The trial is now open to individuals between the ages of 12-35 who have been diagnosed with new-onset type 1 diabetes within the past 3 months.  The START trial is being conducted under the direction of principal investigator Dr.

Results of the ITN's study of a novel vaccine for treatment of new onset type 1 diabetes has been published in the Journal of Autoimmunity. Led by Joslin Diabetes Clinic's Tihamer Orban, the study determined that a vaccine comprised of insulin B-chain in incomplete Freund's adjuvant was generally safe and well-tolerated.

The Immune Tolerance Network (ITN) is seeking ‘Proposal Outlines’ for novel clinical trials designed to induce immune tolerance in psoriasis and other autoimmune skin disorders, including those mediated by autoantibodies such as pemphigus and pemphigoid.A special assessment group has been convened by the ITN to consider these proposals.